143 related articles for article (PubMed ID: 20298476)
41. Neuronal markers are expressed in human gliomas and NSE knockdown sensitizes glioblastoma cells to radiotherapy and temozolomide.
Yan T; Skaftnesmo KO; Leiss L; Sleire L; Wang J; Li X; Enger PØ
BMC Cancer; 2011 Dec; 11():524. PubMed ID: 22185371
[TBL] [Abstract][Full Text] [Related]
42. Upregulation of DLX2 confers a poor prognosis in glioblastoma patients by inducing a proliferative phenotype.
Yan ZH; Bao ZS; Yan W; Liu YW; Zhang CB; Wang HJ; Feng Y; Wang YZ; Zhang W; You G; Zhang QG; Jiang T
Curr Mol Med; 2013 Mar; 13(3):438-45. PubMed ID: 23331016
[TBL] [Abstract][Full Text] [Related]
43. Platelet-derived growth factor receptor α/glial fibrillary acidic protein expressing peritumoral astrocytes associate with shorter median overall survival in glioblastoma patients.
Leiss L; Mega A; Olsson Bontell T; Nistér M; Smits A; Corvigno S; Rahman MA; Enger PØ; Miletic H; Östman A
Glia; 2020 May; 68(5):979-988. PubMed ID: 31769546
[TBL] [Abstract][Full Text] [Related]
44. Cytochrome P450 1B1 expression in glial cell tumors: an immunotherapeutic target.
Barnett JA; Urbauer DL; Murray GI; Fuller GN; Heimberger AB
Clin Cancer Res; 2007 Jun; 13(12):3559-67. PubMed ID: 17575219
[TBL] [Abstract][Full Text] [Related]
45. Low HER2-expressing glioblastomas are more often secondary to anaplastic transformation of low-grade glioma.
Mineo JF; Bordron A; Baroncini M; Maurage CA; Ramirez C; Siminski RM; Berthou C; Dam Hieu P
J Neurooncol; 2007 Dec; 85(3):281-7. PubMed ID: 17571214
[TBL] [Abstract][Full Text] [Related]
46. Divergent differentiation in pleomorphic xanthoastrocytoma. Evidence for a neuronal element and possible relationship to ganglion cell tumors.
Powell SZ; Yachnis AT; Rorke LB; Rojiani AM; Eskin TA
Am J Surg Pathol; 1996 Jan; 20(1):80-5. PubMed ID: 8540612
[TBL] [Abstract][Full Text] [Related]
47. The evolution of the histology in pleomorphic xanthoastrocytomas in children: a study of 15 cases.
Wu X; Bandopadhayay P; Ng J; Ashley D; Chow CW
Pathology; 2011 Jan; 43(1):9-16. PubMed ID: 21240059
[TBL] [Abstract][Full Text] [Related]
48. CD34 and microtubule-associated protein 2 expression in dysembryoplastic neuroepithelial tumours with an emphasis on dual expression in non-specific types.
Sung CO; Suh YL; Hong SC
Histopathology; 2011 Aug; 59(2):308-17. PubMed ID: 21884210
[TBL] [Abstract][Full Text] [Related]
49. Prognostic implications of the DNA damage response pathway in glioblastoma.
Seol HJ; Yoo HY; Jin J; Joo KM; Kong DS; Yoon SJ; Yang H; Kang W; Lim DH; Park K; Kim JH; Lee JI; Nam DH
Oncol Rep; 2011 Aug; 26(2):423-30. PubMed ID: 21617879
[TBL] [Abstract][Full Text] [Related]
50. p53 immunohistochemical positivity as a prognostic marker in intracranial tumours.
Soini Y; Niemelä A; Kamel D; Herva R; Bloigu R; Pääkkö P; Vähäkangas K
APMIS; 1994 Oct; 102(10):786-92. PubMed ID: 7826609
[TBL] [Abstract][Full Text] [Related]
51. New variants of malignant glioneuronal tumors: a clinicopathological study of 40 cases.
Varlet P; Soni D; Miquel C; Roux FX; Meder JF; Chneiweiss H; Daumas-Duport C
Neurosurgery; 2004 Dec; 55(6):1377-91: discussion 1391-2. PubMed ID: 15574220
[TBL] [Abstract][Full Text] [Related]
52. Immunohistochemical study of central neurocytoma, subependymoma, and subependymal giant cell astrocytoma.
You H; Kim YI; Im SY; Suh-Kim H; Paek SH; Park SH; Kim DG; Jung HW
J Neurooncol; 2005 Aug; 74(1):1-8. PubMed ID: 16078101
[TBL] [Abstract][Full Text] [Related]
53. Identification of blood protein biomarkers that aid in the clinical assessment of patients with malignant glioma.
Xu BJ; An QA; Srinivasa Gowda S; Yan W; Pierce LA; Abel TW; Rush SZ; Cooper MK; Ye F; Shyr Y; Weaver KD; Thompson RC
Int J Oncol; 2012 Jun; 40(6):1995-2003. PubMed ID: 22307528
[TBL] [Abstract][Full Text] [Related]
54. IGF-IR: a new prognostic biomarker for human glioblastoma.
Maris C; D'Haene N; Trépant AL; Le Mercier M; Sauvage S; Allard J; Rorive S; Demetter P; Decaestecker C; Salmon I
Br J Cancer; 2015 Sep; 113(5):729-37. PubMed ID: 26291053
[TBL] [Abstract][Full Text] [Related]
55. Differential expression of S100 calcium-binding proteins characterizes distinct clinical entities in both WHO grade II and III astrocytic tumours.
Camby I; Lefranc F; Titeca G; Neuci S; Fastrez M; Dedecken L; Schäfer BW; Brotchi J; Heizmann CW; Pochet R; Salmon I; Kiss R; Decaestecker C
Neuropathol Appl Neurobiol; 2000 Feb; 26(1):76-90. PubMed ID: 10736069
[TBL] [Abstract][Full Text] [Related]
56. Immunohistochemical localization of glial fibrillary acidic protein in human glial neoplasms.
Velasco ME; Dahl D; Roessmann U; Gambetti P
Cancer; 1980 Feb; 45(3):484-94. PubMed ID: 6243508
[TBL] [Abstract][Full Text] [Related]
57. Diagnostic delay and survival in high-grade gliomas - evidence of the 'waiting time paradox'?
Aggarwal A; Herz N; Campbell P; Arkush L; Short S; Rees J
Br J Neurosurg; 2015; 29(4):520-3. PubMed ID: 25738427
[TBL] [Abstract][Full Text] [Related]
58. Pleomorphic xanthoastrocytoma with a gangliomatous component: an immunohistochemical and ultrastructural study.
Kordek R; Biernat W; Sapieja W; Alwasiak J; Liberski PP
Acta Neuropathol; 1995; 89(2):194-7. PubMed ID: 7732793
[TBL] [Abstract][Full Text] [Related]
59. Serum concentrations of glial fibrillary acidic protein (GFAP) do not indicate tumor recurrence in patients with glioblastoma.
Vietheer JM; Rieger J; Wagner M; Senft C; Tichy J; Foerch C
J Neurooncol; 2017 Oct; 135(1):193-199. PubMed ID: 28717884
[TBL] [Abstract][Full Text] [Related]
60. Low expression of tissue inhibitor of metalloproteinases-1 (TIMP-1) in glioblastoma predicts longer patient survival.
Aaberg-Jessen C; Christensen K; Offenberg H; Bartels A; Dreehsen T; Hansen S; Schrøder HD; Brünner N; Kristensen BW
J Neurooncol; 2009 Oct; 95(1):117-128. PubMed ID: 19430729
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
